HealthyTogether: Dyadic 14-week virtual weight-loss program for Veterans and a support person

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

HealthyTogether is a randomized interventional program that enrolls Veterans with obesity together with a close family member or friend to participate in an eight-session virtual weight-management program delivered over 14 weeks. Participants are randomized to the dyadic HealthyTogether intervention or a comparison condition and are followed for changes in body weight, physical activity, diet, and relationship quality. The intervention emphasizes behavior change skills, social support, and improved communication within the dyad to promote sustained weight-related behavior changes. Outcomes are measured using VA medical-record weights and validated surveys of diet, activity, and relationship functioning.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Veteran participants:

* Assigned to a VA primary care provider
* Have a weight measurement (BMI\>=30) recorded in the VA medical record within 16 weeks prior to enrollment
* Have a second, valid weight measurement recorded in the VA medical record within the prior year
* Have a BMI\>=30 at enrollment
* Able to participate in virtual intervention sessions during regular business hours

Partner participants:

* Able to participate in virtual intervention sessions during regular business hours
* Speak with Veteran at last weekly
* Live in the same state where Veteran receives VA care

Exclusion Criteria:

Veterans are excluded if:

* not fluent in English
* have severe hearing loss prohibiting participation
* have a dementia diagnosis
* have recently (within the past 3 months) participated in a clinical or research behavioral weight management program
* have a history of (within past 2 years) or plans to (within next 6 months) have bariatric surgery
* are pregnant, postpartum, nursing, or planning to become pregnant within 6 months
* are receiving cancer (non-skin) treatment
* have drug or alcohol dependence not in remission, a recent suicide attempt, active psychosis, or an active behavior flag in the medical record
* report high-levels of alcohol use (AUDIT-C score \>=8)
* are receiving hospice or palliative care
* are living in a nursing home or assisted living facility
* are enrolled in VA home-based primary care
* have end stage renal disease
* have a current or past diagnosis of anorexia or bulimia
* have had an inpatient hospitalization in the past 3 months
* weigh more than 440 pounds (this is the upper limit of the study's scales)

Partners are excluded if:

* not fluent in English
* have severe hearing loss prohibiting participation
* endorse having a health condition that may limit their ability to participate in the intervention
* report high-levels of current alcohol use (AUDIT-C score \>=8)
* are receiving hospice or palliative care
* are living in a nursing home or assisted living facility

Where it's running

• Rocky Mountain Regional VA Medical Center, Aurora, CO
  Aurora, Colorado, United States Recruiting
• VA Puget Sound Health Care System Seattle Division, Seattle, WA
  Seattle, Washington, United States Recruiting

Study contacts

• Principal investigator: Kristen E. Gray, PhD MS BS — VA Puget Sound Health Care System Seattle Division, Seattle, WA
• Study coordinator: Kristen E Gray, PhD MS BS
• Email: Kristen.Gray2@va.gov
• Phone: (206) 764-2056

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

• EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes

  This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.

  Recruiting Phase 3 Eli Lilly and Company · Tucson, Arizona and 74 other locations · NCT07881458

• Monthly dose of PF-08653944 vs placebo in Chinese adults who are overweight or obese

  This study tests whether berobenatide (PF-08653944) given once a month helps adults in China lose weight compared with a placebo.

  Recruiting Phase 3 Pfizer · Hefei, Anhui and 5 other locations · NCT07874633

• FutureShape Family: a family-based weight-management program with semaglutide for children and parents

  This trial tests whether a family-centered program that combines a prescription medication (semaglutide) with lifestyle support and app-based coaching can help adults with obesity and their children who are overweight/obese.

  Recruiting Phase 4 University of Copenhagen · Copenhagen · NCT07872904

• Home self-administration of a weight-management medicine with an autoinjector in adults who are overweight or obese

  This study tests whether adults who are overweight or have obesity can successfully self-administer maridebart cafraglutide at home using an autoinjector.

  Recruiting at 25 sites Phase 3 Amgen · San Diego, California and 24 other locations · NCT07871409

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.